Canadian Manufacturing

Trudeau says no ‘silver bullet’ to vaccinate world amid debate on patent rules

The Canadian Press

Manufacturing Operations Procurement Infrastructure biomanufacturing COVID-19 healthcare Manufacturing pandemic Pharmaceutical Manufacturing pharmaceuticals vaccine manufacturing

The World Trade Organization is in talks about temporarily waiving intellectual property rights around vaccines.

Prime Minister Justin Trudeau spent his last day in Europe on June 15 thanking leaders and local workers for getting COVID-19 vaccines to Canada, saying there is no “silver bullet” that results in shots being available around the world.

Trudeau visited the manufacturing facility in Puurs, Belgium, where Canada’s supply of the Pfizer-BioNTech vaccine was produced until the United States started shipping doses early last month.

Around 11.6 million vaccines produced at the facility made their way to Canada after being approved last December.

Canada faced bumps in its vaccination campaign earlier this year when a slowdown at the production plant in Belgium disrupted delivery plans.


Since then, the volume of vaccines flowing into Canada has steadily risen. This week alone, Canada is set to receive 2.4 million doses from Pfizer-BioNTech, which has consistently delivered large weekly shipments since mid-March.

Getting more of the world vaccinated against COVID-19 faster, especially those living in less wealthy countries than major democracies like Canada, was the main mandate of an earlier Group of Seven leaders’ summit Trudeau attended in Cornwall, U.K.

There he said Canada had committed $2.5 million in international pandemic-related aid to buy 87 million doses to go to poorer countries. He also announced plans for Canada to donate almost 13 million doses through the global vaccine-sharing alliance known as COVAX.

It’s a relatively small amount considering Canada, with 38 million people, has contracts to buy 251 million doses from pharmaceutical companies.

Speaking on June 15 after a separate Canada-EU summit with European leaders, Trudeau said getting everyone around the world vaccinated as quickly as possible is complex, demonstrated by the discussion around loosening the rules around COVID-19 vaccine patents.

“It’s not just finding a single silver bullet that’s going to suddenly result in finding vaccines everywhere around the world,” he said. “There are complexities that need to be worked through.”

The World Trade Organization is in talks about temporarily waiving intellectual property rights around vaccines. Supporters say it would make it easier for developing countries to import the expertise, equipment and ingredients necessary to make their own COVID-19 vaccines.

European leaders have presented an alternative to the idea from Africa and India. They believe a better solution is compulsory licensing, which is when a government OKs someone else making a patent-protected product without the owner’s permission.

The Canadian government has confirmed it’s in on the WTO talks around waiving vaccine patents, but after being asked repeatedly, Trudeau has yet to reveal Ottawa’s position.


Stories continue below